Company facts
- Industry
- Pharmaceutical Preparations
- Headquarters
- Rahway, New Jersey
- Most recent report
- 10-Q, filed Aug 7, 2026
- Incorporated
- New Jersey
- Filings on record
- 1,011+ filings
- On EDGAR
- CIK 310158
- Fiscal year ends
- December
- Filer status
- Large accelerated filer
Financials 8 of 35
News 8 of 68
Prospectuses and Registrations 8 of 31
- 424B5 Prospectus supplement for an offering May 20, 2026
- FWP Free writing prospectus May 19, 2026
- 424B5 Prospectus supplement for an offering May 18, 2026
- 424B5 Prospectus supplement for an offering Dec 3, 2025
- FWP Free writing prospectus Dec 2, 2025
- 424B5 Prospectus supplement for an offering Dec 1, 2025
- 424B5 Prospectus supplement for an offering Sep 4, 2025
- FWP Free writing prospectus Sep 3, 2025
Proxies 8 of 32
- DEFA14A Extra proxy material Apr 8, 2026
- DEF 14A Proxy statement for a shareholder vote Apr 8, 2026
- PX14A6G Shareholder's own proxy material May 7, 2025
- PX14A6G Shareholder's own proxy material Apr 24, 2025
- PX14A6G Shareholder's own proxy material Apr 14, 2025
- DEFA14A Extra proxy material Apr 9, 2025
- DEF 14A Proxy statement for a shareholder vote Apr 9, 2025
- DEFA14A Extra proxy material Apr 11, 2024
Ownership 8 of 780
- 3 Insider reported their initial holding Sep 1, 2026
- 4 Insider reported a trade Aug 13, 2026
- 144 Notice of a proposed sale of restricted stock Aug 13, 2026
- 4 Insider reported a trade Aug 13, 2026
- 144 Notice of a proposed sale of restricted stock Aug 12, 2026
- 144 Notice of a proposed sale of restricted stock Aug 12, 2026
- 4 Insider reported a trade Aug 12, 2026
- 144 Notice of a proposed sale of restricted stock Aug 11, 2026
Other 8 of 65
- 11-K Employee stock plan report Jun 24, 2026
- 11-K Employee stock plan report Jun 24, 2026
- 11-K Employee stock plan report Jun 24, 2026
- SD Conflict minerals disclosure May 29, 2026
- SC TO-T/A Amended filing May 5, 2026
- SC TO-T/A Amended filing Apr 24, 2026
- ARS Annual report sent to shareholders Apr 8, 2026
- SC TO-T Apr 7, 2026
What to read: Jun 2026 10-Q
SECSift found 2 of 10 sections worth reading, with 1 positive, 3 notable, and 5 negative flags.
Financial Statements (Item 1)
Full interim financials and notes with company-specific results and risks.Negative- Januvia and Janumet lost U.S. exclusivity in May 2026; Janumet XR in July 2026.
- German court granted Halozyme preliminary injunction against subcutaneous pembrolizumab sales.
- Lenvima compound patent expired April 2026; generic risk partially settled to July 2030.
- IRS proposed $1.3B transition tax adjustment plus $260M penalties; Merck contests.
Management's Discussion (Item 2)
Dense MD&A with GAAP loss, acquisition R&D charges, Keytruda/Gardasil trends, tax dispute.PositiveNotable
What changed: Jun 2026 vs. Mar 2026
About 12% of MRK's Jun 2026 10-Q is new information. 56 paragraphs were added, 178 changed, and 52 removed. Below are the most important lines SECSift identified.
New
- Terns acquisition closed in May 2026; Merck recorded $5.7B R&D charge ($2.31 per share). Item 2
- TARGAN acquisition announced July 2026 for ~$650M, expected to close in H2 2026. Item 1
- Terns acquisition closed May 2026; $5.7B R&D charge recorded in Q2 2026. Item 1
- Company signed GENEROUS Model agreement with CMS in June 2026 for Medicaid pricing. Item 2
- FDA approved Lipfendra (oral PCSK9 inhibitor) in July 2026 for hypercholesterolemia. Item 2
Everything here comes from Merck & Co., Inc.'s own filings on SEC EDGAR. The filing list is rechecked every hour. SECSift analysis was completed on Aug 20, 2026, from the 10-Q for Jun 2026.